查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1869787

神經科學抗體和檢測市場規模、佔有率和趨勢分析報告：產品、技術、應用、地區和細分市場預測（2025-2033 年）

Neuroscience Antibodies And Assays Market Size, Share & Trends Analysis Report By Product (Consumable, Instrument), By Technology (Immunoassays & Immunochemistry, Molecular diagnostics), By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

神經科學抗體和檢測市場摘要

2024 年全球神經科學抗體和檢測市場規模為 37.2343 億美元，預計從 2025 年到 2033 年將達到 58.6703 億美元，複合年成長率為 5.41%。

市場成長的促進因素是阿茲海默症、帕金森氏症、多發性硬化症、神經發炎和精神疾病等神經系統疾病和神經退化性疾病疾病的日益普遍，這些疾病在全球範圍內呈上升趨勢。

隨著人口老化和診斷技術的進步，對支持疾病早期檢測和藥物研發的工具的需求日益成長。此外，政府和機構不斷加強監管和資金投入，也推動了對關鍵平台技術（例如抗體和檢測方法）的需求，以支持神經科學的研究和開發。政府支出的增加和研發計劃的擴展也促進了市場成長。阿茲海默症率的上升是市場擴張的關鍵促進因素之一。隨著全球人口老化，對早期、精準診斷工具的需求日益成長。根據阿茲海默症協會2024年的預測，美國阿茲海默症患者人數將急劇增加，而且失智症的風險會隨著老齡化的成長而增加。預計65歲及以上人口將從2022年的5,800萬增加到2050年的8,200萬人。嬰兒潮世代（1946年至1964年出生）是老年失智症失智症風險最高的一代，到2030年，他們都將年滿65歲或以上。

此外，技術進步顯著改善了多發性硬化症 (MS) 的診斷和監測，為預測期內 MS 診斷市場創造了巨大的成長機會。磁振造影 (MRI)、神經生理監測、智慧型手機應用程式、輔助機器人設備以及經顱直流電刺激 (tDCS) 等神經治療評估方法等先進技術，均有助於早期檢測、患者病患監測和症狀管理。推動市場擴張的關鍵因素之一是全球 MS 發病率的不斷上升以及由此產生的對快速準確診斷解決方案的需求。根據國際多發性硬化症聯盟 (MS International Federation) 估計，2013 年 MS 患者人數為 230 萬，2020 年為 280 萬，2023 年為 290 萬。

研發投入的不斷增加，尤其是在創新成像技術、生物標記檢測和數位監測平台開發方面的投入，進一步推動了市場擴張。政府主導的旨在改善診斷服務可近性的措施、技術進步以及醫療基礎設施的改善，也是全球多發性硬化症診斷市場成長的推動因素。為了進一步推進神經退化性疾病的研究，貝克曼庫爾特診斷公司於2025年1月推出了一系列基於血液的「僅供研究使用（RUO）」生物標記免疫檢測。這些檢測旨在評估關鍵生物標記，例如p-Tau217、GFAP、NfL和APOEε4，這些標記正逐漸成為阿茲海默症和其他神經退化性疾病的重要標記物。

貝克曼庫爾特推出這項檢測方法，彰顯了其致力於為研究人員提供尖端儀器的承諾，這些儀器能夠以卓越的靈敏度和特異性識別和測量生物標記。透過精確測量這些生物標記，該檢測方法有助於更深入地了解疾病機制，並支持早期診斷技術和個人化治療方案的開發。此檢測方法與貝克曼庫爾特的免疫檢測分析儀相容，可輕鬆融入現有實驗室工作流程，進而提高神經退化性疾病研究的效率和效果。

此外，主要企業推出的新產品正在改善市場供應和競爭格局，從而推動市場擴張。例如，超靈敏生物標記檢測公司 Quantelix 於 2022 年 7 月宣布，已完成檢查室自建檢驗(LDT) 的驗證，該檢測用於定量測量血漿中的磷酸化Tau -181 (pTau-181)。此檢測可用於阿茲海默症的診斷評估。此 LDT 採用定量免疫檢測測量人類血漿中 pTau-181 的濃度，是美國首個臨床應用的此類檢測。預計這些用於神經系統疾病的免疫檢測診斷技術的進步將在預測期內推動市場更快成長。

同樣，2021年11月，Fujirebio Europe NV在其Innotest平台上推出了兩款阿茲海默症免疫檢測，這是該公司與Adx Neurosciences NV合作以來的首批產品。這兩款檢測產品旨在測量與突觸功能障礙和神經發炎相關的兩種生物標記物，而突觸功能障礙和神經發炎是阿茲海默症進展的關鍵過程：神經元五聚蛋白-2 (NPTX2) 和可溶性觸發受體表達髓系細胞2 (STREM2)。這些創新可望助力阿茲海默症治療藥物的研發。因此，針對神經科學生物標記的新型免疫檢測解決方案的持續推廣應用，預計將在未來幾年顯著推動市場成長。

目錄

第1章 神經科學抗體和檢測市場：調查方法和範圍

2. 神經科學抗體與檢測市場：執行摘要

  • 市場概述
  • 產品與技術概覽
  • 最終用途簡介
  • 競爭格局概覽

3. 神經科學抗體和檢測市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
  • 市場促進因素分析
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 市場限制因素分析
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第4章 神經科學抗體與檢測市場：產品估算與趨勢分析

  • 神經科學抗體和檢測市場：產品差異分析
  • 消耗品
  • 裝置

第5章 神經科學抗體與檢測市場：技術預測與趨勢分析

  • 神經科學抗體與檢測市場：技術波動分析
  • 免疫檢測和免疫化學
  • 分子診斷
  • 臨床化學及其他相關檢測平台
  • 其他新興/超靈敏平台

6. 神經科學抗體和檢測市場：終端用途估算和趨勢分析

  • 神經科學抗體和檢測市場：最終用途差異分析
  • 學術研究機構
  • 診斷實驗室
  • 其他

7. 神經科學抗體與檢測市場：區域業務分析

  • 區域市場概況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第8章 競爭情勢

  • 公司分類
  • 策略規劃
    • 新產品上市
    • 夥伴關係
    • 獲得
    • 合作
    • 資金籌措
  • 主要企業市佔率分析，2024 年
  • 公司熱力圖分析
  • 公司簡介
    • Thermo Fisher Scientific
    • Bio-Rad Laboratories, Inc.
    • Merck KGaA
    • F. Hoffmann-La Roche
    • Cell Signaling Technology, Inc.
    • BioLegend, Inc.
    • Exalenz Bioscience Ltd（meridian bioscience）
    • Abcam Plc
    • Rockland Immunochemicals, Inc.
    • GENSCRIPT
    • SANTA CRUZ BIOTECHNOLOGY, INC.
Product Code: GVR-4-68040-764-2

Neuroscience Antibodies And Assays Market Summary

The global neuroscience antibodies and assays market size was valued at USD 3,723.43 million in 2024 and is expected to reach USD 5,867.03 million, growing at a CAGR of 5.41% from 2025 to 2033. The market is driven by the rising prevalence of neurological and neurodegenerative disorders globally-conditions like Alzheimer's, Parkinson's, multiple sclerosis, neuroinflammation, psychiatric disorders, etc.

As populations age and as diagnostic capabilities improve, there is increasing demand for tools that can detect disease earlier and help in drug discovery. Also, regulatory pressures and funding from governments and institutions are growing, which support neuroscience R&D and hence require antibodies/assays as key enabling components. Growth is also being accelerated by rising government spending and R&D projects. One major factor propelling the market's expansion is the increasing incidence of Alzheimer's disease. The need for early and precise diagnostic tools keeps growing as the world's population ages. The 2024 Alzheimer's Association predicts that the number of Americans with Alzheimer's will increase dramatically and that dementia risk increases with age. The number of people 65 and older is expected to increase from 58 million in 2022 to 82 million by 2050. The age group most vulnerable to Alzheimer's dementia, baby boomers (those born between 1946 and 1964), will all be 65 or older by 2030.

Furthermore, technological advancements are greatly improving MS diagnosis and monitoring, and during the forecast period, they are anticipated to generate significant growth opportunities in the MS diagnostics market. Early detection, patient monitoring, and symptom management have all been enhanced by cutting-edge technologies like MRI-based imaging, neurophysiological monitoring, smartphone applications, assistive robotic devices, and neurotherapeutic assessment methods like transcranial direct current stimulation (tDCS). One of the main factors propelling market expansion is the increasing incidence of MS worldwide and the corresponding rise in the need for prompt and precise diagnostic solutions. There were 2.3 million MS patients in 2013, 2.8 million in 2020, and 2.9 million in 2023, according to the MS International Federation.

Increased investment in R&D, especially in the creation of innovative imaging methods, biomarker assays, and digital monitoring platforms, supports market expansion even more. The global MS diagnostics market is also growing as a result of expanding government initiatives to improve access to diagnostic services, technological advancements, and improved healthcare infrastructure. To further the study of neurodegenerative diseases, Beckman Coulter Diagnostics introduced a new line of blood-based Research Use Only (RUO) biomarker immunoassays in January 2025. These tests are intended to evaluate important biomarkers that are becoming important markers in neurodegenerative diseases, such as Alzheimer's disease, including p-Tau217, GFAP, NfL, and APOE ε4.

Beckman Coulter's dedication to giving researchers top-notch instruments to identify and measure biomarkers with remarkable sensitivity and specificity is demonstrated by the launch of these assays. The assays support the development of early diagnostic techniques and individualized treatment plans by providing accurate measurement of these biomarkers, which contributes to a deeper understanding of disease mechanisms. These assays' compatibility with Beckman Coulter's Immunoassay Analyzers guarantees integration with current laboratory workflows, improving the efficacy and efficiency of research on neurodegenerative diseases.

Furthermore, by improving availability and competitive dynamics, major players' introduction of new products has been facilitating market expansion. For instance, the ultrasensitive biomarker detection company Quanterix Corporation announced in July 2022 that a laboratory-developed test (LDT) that measures phospho-Tau 181 (pTau-181) in plasma quantitatively has been validated. This test will aid in the diagnostic evaluation of Alzheimer's disease. This LDT uses a quantitative immunoassay format to measure the levels of pTau-181 in human plasma and was first made available for clinical use in the United States. During the forecast period, the market is expected to grow more quickly due to these developments in immunoassay-based diagnostics for neurological conditions.

Similarly, in November 2021, Fujirebio Europe NV launched two Alzheimer's disease immunoassays on its Innotest platform, marking the first product release following its collaboration with Adx Neurosciences NV. The assays are designed to measure neuronal pentraxin-2 (NPTX2) and soluble triggering receptor expressed on myeloid cells 2 (STREM2), two biomarkers linked to synaptic dysfunction and neuroinflammation key processes associated with Alzheimer's progression. These innovations are expected to complement ongoing therapeutic development efforts for Alzheimer's disease. Consequently, the continued rollout of novel immunoassay solutions targeting neuroscience biomarkers is anticipated to significantly drive market growth over the coming years.

Global Neuroscience Antibodies And Assays Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global neuroscience antibodies and assays market based on product, technology, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Consumables
  • Instruments
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Immunoassays & immunochemistry
  • Molecular Diagnostics
  • Clinical Chemistry & other related detection platforms
  • Other emerging / ultrasensitive platforms
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Firms
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Neuroscience Antibodies and Assays Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Segment
      • 1.1.1.2. Technology Segment
      • 1.1.1.3. Sample Product segment
      • 1.1.1.4. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Neuroscience Antibodies and Assays Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product and Technology Snapshot
  • 2.3. End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Neuroscience Antibodies and Assays Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
  • 3.5. Market Dynamics
    • 3.5.1. Market driver analysis
      • 3.5.1.1. Rising incidence of neurological diseases
      • 3.5.1.2. Increasing research and development activities
      • 3.5.1.3. Growth in the pharmaceutical and biotechnology industries
    • 3.5.2. Market restraint analysis
      • 3.5.2.1. High cost of diagnostics test
  • 3.6. Market Restraint Analysis
  • 3.7. Porter's Five Forces Analysis
  • 3.8. PESTLE Analysis
  • 3.9. Pipeline Analysis

Chapter 4. Neuroscience Antibodies and Assays Market: Product Estimates & Trend Analysis

  • 4.1. Neuroscience Antibodies and Assays Market: Product Movement Analysis
  • 4.2. Consumables
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Instruments
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Neuroscience Antibodies and Assays Market: Technology Estimates & Trend Analysis

  • 5.1. Neuroscience Antibodies and Assays Market: Technology Movement Analysis
  • 5.2. Immunoassays & immunochemistry
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Molecular Diagnostics
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Clinical Chemistry & other related detection platforms
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Other emerging / ultrasensitive platforms
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Neuroscience Antibodies and Assays Market: End Use Estimates & Trend Analysis

  • 6.1. Neuroscience Antibodies and Assays Market: End Use Movement Analysis
  • 6.2. Academic & Research Institutes
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Diagnostics Laboratories
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Others
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Neuroscience Antibodies and Assays Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Neuroscience Antibodies and Assays Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Reimbursement Scenario
      • 7.2.4.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-Pacific Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. NEW PRODUCT LAUNCH
    • 8.2.2. PARTNERSHIPS
    • 8.2.3. ACQUISITION
    • 8.2.4. COLLABORATION
    • 8.2.5. FUNDING
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. Thermo Fisher Scientific
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Bio-Rad Laboratories, Inc.
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Merck KGaA
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. F. Hoffmann-La Roche
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Cell Signaling Technology, Inc.
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. BioLegend, Inc.
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Exalenz Bioscience Ltd (meridian bioscience)
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Abcam Plc
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Rockland Immunochemicals, Inc.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. GENSCRIPT
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. SANTA CRUZ BIOTECHNOLOGY, INC.
      • 8.5.11.1. Company Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviation
  • Table 3 Global Neuroscience Antibodies and Assays Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 5 Global Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 6 Global Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Neuroscience Antibodies and Assays Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 9 North America Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 10 North America Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 U.S. Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 12 U.S. Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 13 U.S. Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 15 Canada Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 16 Canada Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Mexico Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 18 Mexico Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 19 Mexico Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Neuroscience Antibodies and Assays Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 22 Europe Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 23 Europe Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 UK Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 25 UK Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 26 UK Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 27 Germany Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 28 Germany Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 29 Germany Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 France Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 31 France Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 32 France Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 33 Italy Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 34 Italy Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 35 Italy Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 36 Spain Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 37 Spain Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 38 Spain Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 Sweden Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 40 Sweden Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 41 Sweden Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Norway Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 43 Norway Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 44 Norway Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Denmark Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 46 Denmark Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 47 Denmark Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Neuroscience Antibodies and Assays Market, By Country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Japan Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 53 Japan Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 54 Japan Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 55 China Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 56 China Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 57 China Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 India Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 59 India Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 60 India Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Australia Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 62 Australia Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 63 Australia Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 64 Thailand Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 65 Thailand Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 66 Thailand Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 South Korea Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 68 South Korea Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 69 South Korea Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 70 Latin America Neuroscience Antibodies and Assays Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 72 Latin America Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 73 Latin America Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 74 Brazil Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 75 Brazil Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 76 Brazil Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 77 Argentina Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 78 Argentina Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 79 Argentina Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 80 MEA Neuroscience Antibodies and Assays Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 MEA Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 82 MEA Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 83 MEA Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 84 South Africa Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 85 South Africa Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 86 South Africa Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 90 UAE Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 91 UAE Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 92 UAE Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global neuroscience antibodies and assays market- Key market driver analysis
  • Fig. 7 Global neuroscience antibodies and assays market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global neuroscience antibodies and assays market - Porter's analysis
  • Fig. 10 Global neuroscience antibodies and assays market - PESTEL analysis
  • Fig. 11 Global neuroscience antibodies and assays market Product outlook key takeaways
  • Fig. 12 Global neuroscience antibodies and assays market: Product movement analysis
  • Fig. 13 Consumables market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Instruments market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Global neuroscience antibodies and assays market technology outlook key takeaways
  • Fig. 16 Global neuroscience antibodies and assays market: technology movement analysis
  • Fig. 17 Immunoassays & immunochemistry market estimates, 2021 - 2033 (USD Million)
  • Fig. 18 Molecular diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 19 Proteomics/metabolomics market estimates, 2021 - 2033 (USD Million)
  • Fig. 20 Imaging-based biomarker assessment market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Global neuroscience antibodies and assays market end use outlook key takeaways
  • Fig. 22 Global neuroscience antibodies and assays market: end use movement analysis
  • Fig. 23 Academic & Research Institutes and diagnostics laboratories market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 Pharmaceutical & biotechnology firms market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Other End-users market estimates, 2021 - 2033 (USD Million)
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 Global Neuroscience Antibodies and Assays market: Regional movement analysis
  • Fig. 28 North America Neuroscience Antibodies and Assays market, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 30 Canada neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 31 Mexico neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 32 Europe neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 33 UK neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 34 Germany neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 35 France neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 36 Spain neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 37 Italy neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 38 Denmark neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 39 Sweden neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 40 Norway neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 41 Asia Pacific neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 42 Japan neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 43 China neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 44 India neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 45 South Korea neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 46 Australia neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 47 Thailand neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 48 Latin America neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 49 Brazil neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 50 Argentina neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 51 MEA neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 52 South Africa neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 53 Saudi Arabia neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 54 UAE neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 55 Kuwait neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 56 Strategy framework